Literature DB >> 17515957

An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity.

Emily C Baechler1, Jason W Bauer, Catherine A Slattery, Ward A Ortmann, Karl J Espe, Jill Novitzke, Steven R Ytterberg, Peter K Gregersen, Timothy W Behrens, Ann M Reed.   

Abstract

Recent studies have shown increased expression of interferon (IFN)-regulated genes in the peripheral blood cells of patients with systemic lupus erythematosus. A similar interferon signature has been observed in affected muscle tissue from patients with dermatomyositis (DM), but it has not yet been determined if this signature extends to the peripheral blood in DM. We performed global gene expression profiling of peripheral blood cells from adult and juvenile DM patients and healthy controls. Several interesting groups of genes were differentially expressed in DM, including genes with immune function, and others that function in muscle or are involved in mitochondrial/oxidative phosphorylation. Investigation of type I IFN-regulated transcripts revealed a striking interferon signature present in most DM patients studied. Levels of type I IFN-regulated proteins were also elevated in DM serum samples. Furthermore, both the transcript and serum protein IFN signatures were associated with disease activity. These data suggest that the IFN signature may be a useful marker for DM disease activity, and that sampling peripheral blood may be a more practical alternative to muscle biopsy for measuring this signature.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17515957      PMCID: PMC1869622          DOI: 10.2119/2006-00085.Baechler

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  46 in total

1.  Significance analysis of microarrays applied to the ionizing radiation response.

Authors:  V G Tusher; R Tibshirani; G Chu
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-17       Impact factor: 11.205

2.  Plasmacytoid dendritic cells (natural interferon- alpha/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions.

Authors:  L Farkas; K Beiske; F Lund-Johansen; P Brandtzaeg; F L Jahnsen
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

3.  Evidence for differential S100 gene over-expression in psoriatic patients from genetically heterogeneous pedigrees.

Authors:  Sabrina Semprini; Francesca Capon; Alessandra Tacconelli; Emiliano Giardina; Angela Orecchia; Rita Mingarelli; Tommaso Gobello; Giovanna Zambruno; Annalisa Botta; Giuseppe Fabrizi; Giuseppe Novelli
Journal:  Hum Genet       Date:  2002-08-21       Impact factor: 4.132

4.  The combination of apoptotic U937 cells and lupus IgG is a potent IFN-alpha inducer.

Authors:  U Båve; G V Alm; L Rönnblom
Journal:  J Immunol       Date:  2000-09-15       Impact factor: 5.422

5.  Self epitopes shared between human skeletal myosin and Streptococcus pyogenes M5 protein are targets of immune responses in active juvenile dermatomyositis.

Authors:  Margherita Massa; Nick Costouros; Federica Mazzoli; Fabrizio De Benedetti; Antonio La Cava; Tho Le; Isme De Kleer; Angelo Ravelli; Margaret Liotta; Sarah Roord; Charles Berry; Lauren M Pachman; Alberto Martini; Salvatore Albani
Journal:  Arthritis Rheum       Date:  2002-11

6.  Presence of cutaneous interferon-alpha producing cells in patients with systemic lupus erythematosus.

Authors:  S Blomberg; M L Eloranta; B Cederblad; K Nordlin; G V Alm; L Rönnblom
Journal:  Lupus       Date:  2001       Impact factor: 2.911

7.  Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1 and -DQA1 allelic profiles and motifs define clinicopathologic groups in caucasians.

Authors:  Terrance P O'Hanlon; Danielle Mercatante Carrick; Frank C Arnett; John D Reveille; Mary Carrington; Xiaojiang Gao; Chester V Oddis; Penelope A Morel; James D Malley; Karen Malley; Jonathan Dreyfuss; Ejaz A Shamim; Lisa G Rider; Stephen J Chanock; Charles B Foster; Thomas Bunch; Paul H Plotz; Lori A Love; Frederick W Miller
Journal:  Medicine (Baltimore)       Date:  2005-11       Impact factor: 1.889

8.  Gene expression profiling in DQA1*0501+ children with untreated dermatomyositis: a novel model of pathogenesis.

Authors:  Zivana Tezak; Eric P Hoffman; Jennica L Lutz; Tamara O Fedczyna; Dietrich Stephan; Eric G Bremer; Irina Krasnoselska-Riz; Ajit Kumar; Lauren M Pachman
Journal:  J Immunol       Date:  2002-04-15       Impact factor: 5.422

Review 9.  Myositis in children.

Authors:  A M Reed
Journal:  Curr Opin Rheumatol       Date:  2001-09       Impact factor: 5.006

10.  Molecular profiles of inflammatory myopathies.

Authors:  S A Greenberg; D Sanoudou; J N Haslett; I S Kohane; L M Kunkel; A H Beggs; A A Amato
Journal:  Neurology       Date:  2002-10-22       Impact factor: 9.910

View more
  123 in total

1.  Defining TNF-α- and LPS-induced gene signatures in monocytes to unravel the complexity of peripheral blood transcriptomes in health and disease.

Authors:  Biljana Smiljanovic; Joachim R Grün; Marta Steinbrich-Zöllner; Bruno Stuhlmüller; Thomas Häupl; Gerd R Burmester; Andreas Radbruch; Andreas Grützkau; Ria Baumgrass
Journal:  J Mol Med (Berl)       Date:  2010-07-17       Impact factor: 4.599

Review 2.  Update on the assessment of children with juvenile idiopathic inflammatory myopathy.

Authors:  Adam M Huber
Journal:  Curr Rheumatol Rep       Date:  2010-06       Impact factor: 4.592

3.  Different strains of Theiler's murine encephalomyelitis virus antagonize different sites in the type I interferon pathway.

Authors:  Spyridon Stavrou; Zongdi Feng; Stanley M Lemon; Raymond P Roos
Journal:  J Virol       Date:  2010-07-07       Impact factor: 5.103

4.  Mast cells and type I interferon responses in the skin of patients with juvenile dermatomyositis: are current therapies just scratching the surface?

Authors:  Lisa G Rider; Frederick W Miller
Journal:  Arthritis Rheum       Date:  2010-09

Review 5.  Treatment of inflammatory myopathy: emerging therapies and therapeutic targets.

Authors:  Siamak Moghadam-Kia; Rohit Aggarwal; Chester V Oddis
Journal:  Expert Rev Clin Immunol       Date:  2015-08-27       Impact factor: 4.473

Review 6.  Immunology in clinic review series; focus on autoinflammatory diseases: update on monogenic autoinflammatory diseases: the role of interleukin (IL)-1 and an emerging role for cytokines beyond IL-1.

Authors:  R Goldbach-Mansky
Journal:  Clin Exp Immunol       Date:  2012-03       Impact factor: 4.330

7.  Type I IFN Is Necessary and Sufficient for Inflammation-Induced Red Blood Cell Alloimmunization in Mice.

Authors:  David R Gibb; Jingchun Liu; Prabitha Natarajan; Manjula Santhanakrishnan; David J Madrid; Stephanie C Eisenbarth; James C Zimring; Akiko Iwasaki; Jeanne E Hendrickson
Journal:  J Immunol       Date:  2017-06-19       Impact factor: 5.422

Review 8.  Understanding Human Autoimmunity and Autoinflammation Through Transcriptomics.

Authors:  Romain Banchereau; Alma-Martina Cepika; Jacques Banchereau; Virginia Pascual
Journal:  Annu Rev Immunol       Date:  2017-01-30       Impact factor: 28.527

Review 9.  Gene-expression profiling in rheumatic disease: tools and therapeutic potential.

Authors:  Jason W Bauer; Hatice Bilgic; Emily C Baechler
Journal:  Nat Rev Rheumatol       Date:  2009-05       Impact factor: 20.543

Review 10.  Novel Therapeutic Options in Treatment of Idiopathic Inflammatory Myopathies.

Authors:  Namita A Goyal; Tahseen Mozaffar
Journal:  Curr Treat Options Neurol       Date:  2018-07-23       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.